earnings
confidence high
sentiment neutral
materiality 0.65
Petros Pharma Q3 net sales fall 37% to $2.2M; net loss narrows to $1.7M
Petros Pharmaceuticals, Inc.
2021-Q3 EPS reported
-$0.08
revenue$8,678,424
- Net sales $2.2M, down from $3.5M YoY; Prescription Medicines net sales declined 47% due to higher allowances and returns.
- Net loss improved to $1.7M vs $3.3M YoY; adjusted EBITDA loss $1.9M.
- Record STENDRA prescriptions and tablet sales; total mg sold up 6% sequentially.
- Completed enrollment of pivotal label comprehension study for OTC switch of STENDRA; no FDA-approved OTC ED drug exists.
- Cash $8.1M at Sep 30; raised $5.3M net in October 2021.